Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Wells Fargo Downgrades NovoCure to Equal-Weight, Lowers Price Target to $14.5

Author: Benzinga Newsdesk | July 25, 2025 09:22am

Wells Fargo analyst Larry Biegelsen downgrades NovoCure (NASDAQ:NVCR) from Overweight to Equal-Weight and lowers the price target from $40 to $14.5.

Posted In: NVCR